Madison S. Carlino is a policy analyst at Reason Foundation. Her work primarily focuses on drug policy in the United States, including psychedelic medicine and marijuana laws.
-
Psychedelic treatment for neurodegenerative disorders
Recent research suggests that psychedelics, such as psilocybin and LSD, show strong potential as effective treatments for neurodegenerative disorders.
-
Ibogaine treatment for opioid use disorder
Policymakers should consider ibogaine as a potential alternative treatment for opioid use disorder.
-
Modernizing psilocybin policy to improve mental health outcomes
Psychedelics have the potential to be more effective than conventional drugs now being used to treat a range of mental health disorders.